Promestriene, also known as estradiol 3-propyl 17β-methyl diether, is a synthetic estrogen which is used topically in a 1% cream formulation for the treatment of vaginal atrophy in women. It is the 3-propyl and 17β-methyl diether of estradiol and does not appear to convert into estradiol in the body. Promestriene promotes epithelial cell growth and regeneration in the vaginal and vulvar tissues, alleviating discomfort related to thinning and inflammation. As a local estrogen therapy, Promestriene is applied directly to affected areas, providing targeted relief with minimal systemic absorption.
During the production and storage of Promestriene, impurities may form, which must be controlled to ensure the drug’s safety and efficacy. Regulatory authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), set guidelines on permissible impurity levels in Promestriene formulations.
Promestriene works by providing localized estrogen to vaginal and vulvar tissues, promoting epithelial cell growth, enhancing tissue hydration, and reducing inflammation. This action helps alleviate symptoms of atrophy and dryness associated with low estrogen levels.
Yes, when used as directed and under medical supervision, vaginal estrogen treatments like Promestriene are considered safe for most patients. They deliver low doses of estrogen locally, minimizing systemic absorption and reducing the risk of side effects commonly associated with systemic estrogen therapies.
Promestriene is typically applied directly to the affected vaginal or vulvar area as a cream, following the instructions provided by a healthcare provider. It is usually applied once or twice daily, and patients should wash their hands before and after use to ensure proper hygiene and avoid accidental transfer.
The English name for Promestriene remains the same as it is the international nonproprietary name (INN) for this synthetic estrogen. It may be available under different brand names in various countries.
